Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.

Details

Serval ID
serval:BIB_F692C709E268
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.
Journal
World Journal of Experimental Medicine
Author(s)
Digklia A., Voutsadakis I.A.
ISSN
2220-315X (Electronic)
ISSN-L
2220-315X
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
4
Number
4
Pages
58-67
Language
english
Notes
Publication types: Journal Article ; Review, pdf:review
Abstract
Chemotherapy given in a metronomic manner can be administered with less adverse effects which are common with conventional schedules such as myelotoxicity and gastrointestinal toxicity and thus may be appropriate for older patients and patients with decreased performance status. Efficacy has been observed in several settings. An opportunity to improve the efficacy of metronomic schedules without significantly increasing toxicity presents with the addition of anti-angiogenic targeted treatments. These combinations rational stems from the understanding of the importance of angiogenesis in the mechanism of action of metronomic chemotherapy which may be augmented by specific targeting of the vascular endothelial growth factor (VEGF) pathway by antibodies or small tyrosine kinase inhibitors. Combinations of metronomic chemotherapy schedules with VEGF pathway targeting drugs will be discussed in this paper.
Pubmed
Create date
11/02/2015 15:37
Last modification date
05/10/2020 6:26
Usage data